Status and phase
Conditions
Treatments
About
The main purpose of this study is to see if Pembrolizumab in combination with chemotherapy (carboplatin and gemcitabine) is safe and effective in treating patients with metastatic triple negative breast cancer.
Pembrolizumab is a drug which may help the immune system to target and destroy cancer cells. Pembrolizumab has been approved by the FDA for the treatment of advanced melanoma and metastatic non-small cell lung cancer. However, it has not been approved as a treatment for breast cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Subject Inclusion Criteria for Part 1: Safety Run-in study
Subject Exclusion Criteria for Part 1: Safety Run-in study
Subject Inclusion Criteria for Part 2 (Randomized Phase II Clinical Trial)
Subject Exclusion Criteria for Part 2 (Randomized Phase II Clinical Trial)
Primary purpose
Allocation
Interventional model
Masking
87 participants in 2 patient groups
Loading...
Central trial contact
Elias Obeid, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal